My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Raloxifene HCl (LY-139481)
    Raloxifene HCl (LY-139481)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1723
    CAS #: 82640-04-8Purity ≥98%

    Description: Raloxifene HCl (also known as LY-156758; LY-139481; trade names: Evista; Keoxifene; RALOX), the hydrochloride salt of Raloxifene, is a selective estrogen antagonist or estrogen strogen receptor modulator (SERM) that has been approved as a medication to prevent and treat osteoporosis in postmenopausal women. It inhibits human cytosolic aldehyde oxidase-catalyzed phthalazine oxidation activity with an IC50 of 5.7 nM. Raloxifene belongs to the benzothiophene class of estrogen strogen receptor modulator (SERM). Raloxifene binds to estrogen receptors as a mixed estrogen agonist/antagonist; it displays both an ER-α-selective partial agonist/antagonist effect and a pure ER-ß-selective antagonist effect. 

    References: Drug Metab Dispos. 2004 Jan;32(1):89-97; Endocrinology. 1996 May;137(5):2075-84.

    Related CAS #: 84449-90-1 (free base); 82640-04-8  or   84449-90-1 (HCl); 174264-50-7 (6-glucuronide); 84449-82-1 (dimethyl ester HCl); 185415-07-0 (4-Monomethyl Ether); 178451-13-3 (6-Monomethyl Ether); 84541-36-6 (Raloxifene Bismethyl Ether HCl, a metabolite of Raloxifene); 84541-38-8 (Raloxifene Bismethyl Ether); 182507-22-8 (Raloxifene 4'-glucuronide); 195454-31-0 (Raloxifene N-Oxide); 182507-20-6 (Raloxifene 6,4'-Bis-β-D-glucuronide); 174264-46-1 (4'-tert-Butyldimethylsilyl-6-hydroxy Raloxifene); 334758-18-8 (6-Raloxifene-β-D-glucopyranoside); 334758-19-9 (4'-Raloxifene-β-D-glucopyranoside); 174264-51-8 [Methyl Raloxifene 4'-(2,3,4-Tri-O-acetyl-β-D-glycopyranuronate)]; 1159977-58-8 [7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene]; 177744-96-6 (LY88074); 63676-25-5 (LY117018)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)510.04
    CAS No.82640-04-8
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 100 mg/mL (196.1 mM)
    Water: <1 mg/mL
    Ethanol: <1 mg/mL
    Solubility (In vivo)1% methylcellulose: 30mg/mL 
    SynonymsLY-156758; LY-139481; LY 156758; LY139481; LY156758 (Keoxifene) HCl; LY 139481; trade names: Evista; Keoxifene; RALOX 

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Raloxifene, has been demonstrated as a potent uncompetitive inhibitor of human liver aldehyde oxidase-catalyzed oxidation of phthalazine, vanillin, and nicotine-Delta1'(5')-iminium ion, with Ki values of 0.87 nM, 1.2 nM and 1.4 nM. Raloxifene has also been shown to be a noncompetitive inhibitor of an aldehyde oxidase-catalyzed reduction reaction of a hydroxamic acid-containing compound, with a Ki of 51 nM. Raloxifene activates TGF beta 3 promoter as a full agonist at nanomolar concentrations, and raloxifene inhibits the estrogen response element-containing vitellogenin promoter expression as a pure estrogen antagonist in transient transfection assays.

    In VivoRaloxifene restores both bone mineral density and TGF beta 3 messenger RNA expression in the femur to levels measured in intact rats. Raloxifene (0.1 mg/kg-10 mg/kg, orally for 5 weeks) increases bone mineral density in the distal femur and proximal tibia in ovariectomized (OVX) rat. Raloxifene reduces serum cholesteroloral with ED50 of 0.2 mg/kg in ovariectomized (OVX) rat. Raloxifene diverges dramatically from estrogen in its lack of significant estrogenic effects on uterine tissue. Raloxifene prevents cancellous osteopenia as well as the changes in radial bone growth, bone resorption, and blood cholesterol, but is less effective in reducing cancellous bone formation and does not prevent uterine atrophy in ovariectomized (OVX) rats. Raloxifene (3 mg/kg/day) has potent estrogenic activity on bone resorption and serum cholesterol, a lesser effect on bone formation, and minimal activity on uterine wet weight in ovariectomized (OVX) rats.
    Animal modelOvariectomized (OVX) rat
    Formulation & DosageDissolved in 1.5% carboxymethylcellulose; 10 mg/kg; Oral gavage

    Drug Metab Dispos. 2004 Jan;32(1):89-97; Endocrinology. 1996 May;137(5):2075-84.

    These protocols are for reference only. InvivoChem does not independently validate these methods.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?